BACKGROUND: HLA antibodies might contribute to the pathogenesis of transfusion-related acute lung injury (TRALI). HLA antibody detection methods include ELISA, flow cytometry, and multiplex bead-based assays, as well as the older lymphocytotoxicity assay, and it is not obvious how to compare results across platforms. STUDY DESIGN AND METHODS: Five hundred twenty-five serum samples were selected from 7841 donors in the Leukocyte Antibody Prevalence Study (LAPS) repository based on risk for the development of HLA antibodies, using the number of pregnancies as the risk factor. Subjects included 81 males and females with 0 (n = 187), 1 (n = 67), or 2+ pregnancies (n = 190). Replicate frozen serum aliquots were sent blinded to four different HLA antibody assay manufacturers for detection using five different assays. RESULTS: The flow cytometry and multiplex bead based-assays typically resulted in a larger proportion of HLA antibody positive samples compared with ELISA based assays. Latent variable analysis was used to derive a new set of consensus cutoffs, which yielded similar sensitivities across test platforms and increased concordance amongst assays. Assay agreement was higher in ever pregnant females than in males and never-pregnant females. CONCLUSIONS: Different assays resulted in varied positivity rates when the manufacturer's suggested cutoffs were used, demonstrating that care needs to be taken when comparing clinical outcomes data generated using different HLA antibody assays and testing platforms. The method used here, involving latent variable analysis, presents one possible approach to calculating comparable cutoffs that result in broad agreement across assays with respect to positivity designation.
BACKGROUND: HLA antibodies might contribute to the pathogenesis of transfusion-related acute lung injury (TRALI). HLA antibody detection methods include ELISA, flow cytometry, and multiplex bead-based assays, as well as the older lymphocytotoxicity assay, and it is not obvious how to compare results across platforms. STUDY DESIGN AND METHODS: Five hundred twenty-five serum samples were selected from 7841 donors in the Leukocyte Antibody Prevalence Study (LAPS) repository based on risk for the development of HLA antibodies, using the number of pregnancies as the risk factor. Subjects included 81 males and females with 0 (n = 187), 1 (n = 67), or 2+ pregnancies (n = 190). Replicate frozen serum aliquots were sent blinded to four different HLA antibody assay manufacturers for detection using five different assays. RESULTS: The flow cytometry and multiplex bead based-assays typically resulted in a larger proportion of HLA antibody positive samples compared with ELISA based assays. Latent variable analysis was used to derive a new set of consensus cutoffs, which yielded similar sensitivities across test platforms and increased concordance amongst assays. Assay agreement was higher in ever pregnant females than in males and never-pregnant females. CONCLUSIONS: Different assays resulted in varied positivity rates when the manufacturer's suggested cutoffs were used, demonstrating that care needs to be taken when comparing clinical outcomes data generated using different HLA antibody assays and testing platforms. The method used here, involving latent variable analysis, presents one possible approach to calculating comparable cutoffs that result in broad agreement across assays with respect to positivity designation.
Authors: Ralph R Vassallo; Susan Hsu; Mindy Einarson; Jonathan Barone; Jaye Brodsky; Gary Moroff Journal: Transfusion Date: 2010-03-12 Impact factor: 3.157
Authors: A Davoren; B R Curtis; I A Shulman; A F Mohrbacher; J Bux; B J Kwiatkowska; J G McFarland; R H Aster Journal: Transfusion Date: 2003-05 Impact factor: 3.157
Authors: E Reed; M Hardy; A Benvenisty; C Lattes; J Brensilver; R McCabe; K Reemstma; D W King; N Suciu-Foca Journal: N Engl J Med Date: 1987-06-04 Impact factor: 91.245
Authors: Christopher C Silliman; Lynn K Boshkov; Zahra Mehdizadehkashi; David J Elzi; William O Dickey; Linda Podlosky; Gwen Clarke; Daniel R Ambruso Journal: Blood Date: 2002-09-05 Impact factor: 22.113
Authors: Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Garth H Utter; Cathy Schechterly; Mila Lebedeva; Eva Operskalski; Naomi L Luban; Harvey Alter; Michael P Busch; Sherrill J Slichter; Philip J Norris Journal: Transfusion Date: 2013-06-30 Impact factor: 3.157
Authors: Danielle M Carrick; Philip J Norris; Robert O Endres; Suchitra Pandey; Steven H Kleinman; David Wright; Yu Sun; Michael P Busch Journal: Transfusion Date: 2011-02-18 Impact factor: 3.157
Authors: Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Mila Lebedeva; John W Heitman; Michael P Busch; Sherrill J Slichter; Philip J Norris Journal: Blood Date: 2013-02-07 Impact factor: 22.113